|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 July 2002, Vol. 100, No. 1, pp. 48-51
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Therapy for chronic graft-versus-host disease: a randomized trial
comparing cyclosporine plus prednisone versus prednisone alone
Sibel Koc,
Wendy Leisenring,
Mary E. D. Flowers,
Claudio Anasetti,
H. Joachim Deeg,
Richard A. Nash,
Jean E. Sanders,
Robert P. Witherspoon,
Rainer Storb,
Frederick R. Appelbaum, and
Paul J. Martin
From the Division of Clinical Research, Fred Hutchinson
Cancer Research Center, and the Department of Medicine, University of
Washington, Seattle, WA.
Results of previous studies have suggested that
transplantation-related mortality among patients with chronic
graft-versus-host disease (GVHD) may be reduced by combined treatment
with cyclosporine (CSP) and prednisone rather than by prednisone alone.
In a randomized trial, we assessed the efficacy of cyclosporine plus
prednisone versus prednisone alone as initial therapy for chronic GHVD
among patients whose platelet counts were higher than 100 000/µL.
Prednisone was administered initially at a dose of 1.0 mg/kg per day
orally, followed by a prolonged taper, and cyclosporine was
administered at 6 mg/kg orally twice daily every other day. The
cumulative incidence of transplantation-related mortality at 5 years
from enrollment was 17% (95% CI, 0.11-0.23) in the CSP plus
prednisone arm and 13% (95% CI, 0.08-0.19) in the prednisone arm. The
hazards of transplantation-related mortality, overall mortality,
recurrent malignancy, secondary therapy, and discontinuation of all
immunosuppressive therapy were not significantly different between the
2 arms, but survival without recurrent malignancy was lower in the
2-drug arm (P = .03). Avascular necrosis developed in 18 (13%) of the 142 patients in the CSP plus prednisone arm and in 32 (22%) of the 145 patients in the prednisone arm
(P = .04). Treatment with CSP plus prednisone may reduce
the risk for steroid-related toxicity, but results of the current study
do not substantiate the hypothesis that the administration of CSP
reduces transplantation-related mortality among patients with chronic GVHD.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Barisione, A. Bacigalupo, E. Crimi, M. T. Van Lint, T. Lamparelli, and V. Brusasco
Changes in lung volumes and airway responsiveness following haematopoietic stem cell transplantation
Eur. Respir. J.,
December 1, 2008;
32(6):
1576 - 1582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Narimatsu, S. Miyakoshi, T. Yamaguchi, M. Kami, T. Matsumura, K. Yuji, N. Murashige, E. Kusumi, Y. Kodama, T. Komatsu, et al.
Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan
Blood,
September 15, 2008;
112(6):
2579 - 2582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Lee and M. E. D. Flowers
Recognizing and Managing Chronic Graft-Versus-Host Disease
Hematology,
January 1, 2008;
2008(1):
134 - 141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Jacobsohn, A. R. Chen, M. Zahurak, S. Piantadosi, V. Anders, J. Bolanos-Meade, M. Higman, J. Margolis, M. Kaup, and G. B. Vogelsang
Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease
J. Clin. Oncol.,
September 20, 2007;
25(27):
4255 - 4261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cutler, D. Miklos, H. T. Kim, N. Treister, S.-B. Woo, D. Bienfang, L. B. Klickstein, J. Levin, K. Miller, C. Reynolds, et al.
Rituximab for steroid-refractory chronic graft-versus-host disease
Blood,
July 15, 2006;
108(2):
756 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Brukamp, A. M. Doyle, R. D. Bloom, N. Bunin, J. E. Tomaszewski, and B. Cizman
Nephrotic Syndrome after Hematopoietic Cell Transplantation: Do Glomerular Lesions Represent Renal Graft-versus-Host Disease?
Clin. J. Am. Soc. Nephrol.,
July 1, 2006;
1(4):
685 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Chien, L. P. Zhao, J. A. Hansen, W. H. Fan, T. Parimon, and J. G. Clark
Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation
Blood,
March 1, 2006;
107(5):
2200 - 2207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Z. Pavletic, S. L. Carter, N. A. Kernan, J. Henslee-Downey, A. M. Mendizabal, E. Papadopoulos, R. Gingrich, J. Casper, S. Yanovich, D. Weisdorf, et al.
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation
Blood,
November 1, 2005;
106(9):
3308 - 3313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Parimon, D. K. Madtes, D. H. Au, J. G. Clark, and J. W. Chien
Pretransplant Lung Function, Respiratory Failure, and Mortality after Stem Cell Transplantation
Am. J. Respir. Crit. Care Med.,
August 1, 2005;
172(3):
384 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror, R. Diaconescu, A. E. Woolfrey, T. R. Chauncey, M. E.D. Flowers, M. Mielcarek, et al.
Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning
J. Clin. Oncol.,
March 20, 2005;
23(9):
1993 - 2003.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Sanders, K. A. Guthrie, P. A. Hoffmeister, A. E. Woolfrey, P. A. Carpenter, and F. R. Appelbaum
Final adult height of patients who received hematopoietic cell transplantation in childhood
Blood,
February 1, 2005;
105(3):
1348 - 1354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Stewart, B. Storer, J. Storek, H. J. Deeg, R. Storb, J. A. Hansen, F. R. Appelbaum, P. A. Carpenter, J. E. Sanders, H.-P. Kiem, et al.
Duration of immunosuppressive treatment for chronic graft-versus-host disease
Blood,
December 1, 2004;
104(12):
3501 - 3506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Baron, J. E. Baker, R. Storb, T. A. Gooley, B. M. Sandmaier, M. B. Maris, D. G. Maloney, S. Heimfeld, D. Oparin, E. Zellmer, et al.
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Blood,
October 15, 2004;
104(8):
2254 - 2262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bhushan and R. H. Collins Jr
Chronic Graft-vs-Host Disease
JAMA,
November 19, 2003;
290(19):
2599 - 2603.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. D. Flowers, S. Lee, and G. Vogelsang
An update on how to treat chronic GVHD
Blood,
September 15, 2003;
102(6):
2312 - 2312.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Akpek, S. J. Lee, M. E. Flowers, S. Z. Pavletic, M. Arora, S. Lee, S. Piantadosi, K. A. Guthrie, J. C. Lynch, A. Takatu, et al.
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study
Blood,
August 1, 2003;
102(3):
802 - 809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Fukuda, M. Boeckh, R. A. Carter, B. M. Sandmaier, M. B. Maris, D. G. Maloney, P. J. Martin, R. F. Storb, and K. A. Marr
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
Blood,
August 1, 2003;
102(3):
827 - 833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Chien, P. J. Martin, T. A. Gooley, M. E. Flowers, S. R. Heckbert, W. G. Nichols, and J. G. Clark
Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med.,
July 15, 2003;
168(2):
208 - 214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mielcarek, P. J. Martin, W. Leisenring, M. E. D. Flowers, D. G. Maloney, B. M. Sandmaier, M. B. Maris, and R. Storb
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
Blood,
July 15, 2003;
102(2):
756 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru
Non-Myeloablative Transplantation
Hematology,
January 1, 2002;
2002(1):
392 - 421.
[Abstract]
[Full Text]
|
 |
|
|
|